Computational Biology and Bioinformatics, IEEE/ACM Transactions on 2012-01-01

A hybrid cellular automaton model of solid tumor growth and bioreductive drug transport.

Nabila Kazmi, M A Hossain, Roger M Phillips

Index: IEEE/ACM Trans. Comput. Biol. Bioinform. 9(6) , 1595-606, (2012)

Full Text: HTML

Abstract

Bioreductive drugs are a class of hypoxia selective drugs that are designed to eradicate the hypoxic fraction of solid tumors. Their activity depends upon a number of biological and pharmacological factors and we used a mathematical modeling approach to explore the dynamics of tumor growth, infusion, and penetration of the bioreductive drug Tirapazamine (TPZ). An in-silico model is implemented to calculate the tumor mass considering oxygen and glucose as key microenvironmental parameters. The next stage of the model integrated extra cellular matrix (ECM), cell-cell adhesion, and cell movement parameters as growth constraints. The tumor microenvironments strongly influenced tumor morphology and growth rates. Once the growth model was established, a hybrid model was developed to study drug dynamics inside the hypoxic regions of tumors. The model used 10, 50 and 100 \mu {\rm M} as TPZ initial concentrations and determined TPZ pharmacokinetic (PK) (transport) and pharmacodynamics (cytotoxicity) properties inside hypoxic regions of solid tumor. The model results showed that diminished drug transport is a reason for TPZ failure and recommend the optimization of the drug transport properties in the emerging TPZ generations. The modeling approach used in this study is novel and can be a step to explore the behavioral dynamics of TPZ.


Related Compounds

  • Tirapazamine

Related Articles:

An innovative three-dimensional gelatin foam culture system for improved study of glioblastoma stem cell behavior.

2015-04-01

[J. Biomed. Mater. Res. B. Appl. Biomater. 103(3) , 618-28, (2015)]

Tirapazamine-doxorubicin interaction referring to heart oxidative stress and Ca²⁺ balance protein levels.

2012-01-01

[Oxid. Med. Cell. Longev. 2012 , 890826, (2012)]

Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine.

1998-06-01

[Br. J. Cancer 77 Suppl 4 , 12-4, (1998)]

Hypoxia-dependent retinal toxicity of NLCQ-1 (NSC 709257) in BALB/c mice. Comparison with tirapazamine.

2011-06-01

[Basic Clin Pharmacol Toxicol. 108(6) , 396-9, (2011)]

Effects of tirapazamine on experimental colorectal liver metastases after radiofrequency ablation (Br J Surg 2012; 99: 567-575).

2012-04-01

[Br. J. Surg. 99(4) , 576, (2012)]

More Articles...